Frost Biologic was founded in 2007 and was originally based on using phenotypic screening to identify small molecules that alter cellular behaviors associated with cancer progression. Since then, Frost has developed robust chemistry and preclinical research capabilities. Molecules derived from this screening approach are thoroughly optimized and put through a rigorous preclinical development program that is designed to yield the best possible clinical candidates.
Despite enormous progress in treating many cancers, survival rates for a number of cancer types remain below 20%. Many major gains in cancer survival result from development of novel chemotherapeutics (cytotoxics and cytostatics), but the industry has shifted focus to developing targeted therapies that work in specific patient populations. At Frost Biologic, we believe that chemotherapeutics will remain the backbone of cancer therapy and that next generation chemotherapeutics are the most likely to make major gains in cancer indications whose high mortality rates still persist.